The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria

A. M. Sefton, J. P. Maskell, A. M. Rafay, A. Whiley, J. D. Williams

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The in-vitro activity of trovafloxacin, a new quinolone, was compared with that of ciprofloxacin, erythromycin, various p-lactam antibiotics and, where appropriate, clindamycin and vancomycin against a range of Gram-positive bacteria including staphylococci (n = 201), Streptococcus pneumoniae (n = 83), β-haemolytic streptococci (n = 46), viridans group streptococci (n = 100), Streptococcus milleri (n = 18) and enterococci (n = 161) by an agar dilution technique. In addition, time-kill studies were performed to estimate the bactericidal activity of trovafloxacin against S. milleri and viridans group streptococci. Trovafloxacin was the most active agent tested against staphylococci. It also showed good activity, at least four-fold and usually eight- to 16-fold that of ciprofloxacin, against all the streptococci. Trovafloxacin showed good activity against vancomycin-sensitive Enterococcus faecalis and Enterococcus faecium, but was less active against the 11 isolates of vancomycin-resistant enterococci. Trovafloxacin showed comparable or superior bactericidal activity to amoxycillin against the S. milleri and viridans group streptococci tested.

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume39
Issue numberSUPPL. B
DOIs
Publication statusPublished - 1997

Fingerprint

Fluoroquinolones
Gram-Positive Bacteria
Streptococcus milleri Group
Viridans Streptococci
Vancomycin
Ciprofloxacin
Streptococcus
Staphylococcus
Indicator Dilution Techniques
Lactams
Enterococcus faecium
Clindamycin
Enterococcus faecalis
Quinolones
Amoxicillin
Enterococcus
Erythromycin
Streptococcus pneumoniae
Agar
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology

Cite this

The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. / Sefton, A. M.; Maskell, J. P.; Rafay, A. M.; Whiley, A.; Williams, J. D.

In: Journal of Antimicrobial Chemotherapy, Vol. 39, No. SUPPL. B, 1997, p. 57-62.

Research output: Contribution to journalArticle

Sefton, A. M. ; Maskell, J. P. ; Rafay, A. M. ; Whiley, A. ; Williams, J. D. / The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. In: Journal of Antimicrobial Chemotherapy. 1997 ; Vol. 39, No. SUPPL. B. pp. 57-62.
@article{3d2cd127f23e4cfda2e72a2038b453b0,
title = "The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria",
abstract = "The in-vitro activity of trovafloxacin, a new quinolone, was compared with that of ciprofloxacin, erythromycin, various p-lactam antibiotics and, where appropriate, clindamycin and vancomycin against a range of Gram-positive bacteria including staphylococci (n = 201), Streptococcus pneumoniae (n = 83), β-haemolytic streptococci (n = 46), viridans group streptococci (n = 100), Streptococcus milleri (n = 18) and enterococci (n = 161) by an agar dilution technique. In addition, time-kill studies were performed to estimate the bactericidal activity of trovafloxacin against S. milleri and viridans group streptococci. Trovafloxacin was the most active agent tested against staphylococci. It also showed good activity, at least four-fold and usually eight- to 16-fold that of ciprofloxacin, against all the streptococci. Trovafloxacin showed good activity against vancomycin-sensitive Enterococcus faecalis and Enterococcus faecium, but was less active against the 11 isolates of vancomycin-resistant enterococci. Trovafloxacin showed comparable or superior bactericidal activity to amoxycillin against the S. milleri and viridans group streptococci tested.",
author = "Sefton, {A. M.} and Maskell, {J. P.} and Rafay, {A. M.} and A. Whiley and Williams, {J. D.}",
year = "1997",
doi = "10.1093/jac/39.suppl_2.57",
language = "English",
volume = "39",
pages = "57--62",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "SUPPL. B",

}

TY - JOUR

T1 - The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria

AU - Sefton, A. M.

AU - Maskell, J. P.

AU - Rafay, A. M.

AU - Whiley, A.

AU - Williams, J. D.

PY - 1997

Y1 - 1997

N2 - The in-vitro activity of trovafloxacin, a new quinolone, was compared with that of ciprofloxacin, erythromycin, various p-lactam antibiotics and, where appropriate, clindamycin and vancomycin against a range of Gram-positive bacteria including staphylococci (n = 201), Streptococcus pneumoniae (n = 83), β-haemolytic streptococci (n = 46), viridans group streptococci (n = 100), Streptococcus milleri (n = 18) and enterococci (n = 161) by an agar dilution technique. In addition, time-kill studies were performed to estimate the bactericidal activity of trovafloxacin against S. milleri and viridans group streptococci. Trovafloxacin was the most active agent tested against staphylococci. It also showed good activity, at least four-fold and usually eight- to 16-fold that of ciprofloxacin, against all the streptococci. Trovafloxacin showed good activity against vancomycin-sensitive Enterococcus faecalis and Enterococcus faecium, but was less active against the 11 isolates of vancomycin-resistant enterococci. Trovafloxacin showed comparable or superior bactericidal activity to amoxycillin against the S. milleri and viridans group streptococci tested.

AB - The in-vitro activity of trovafloxacin, a new quinolone, was compared with that of ciprofloxacin, erythromycin, various p-lactam antibiotics and, where appropriate, clindamycin and vancomycin against a range of Gram-positive bacteria including staphylococci (n = 201), Streptococcus pneumoniae (n = 83), β-haemolytic streptococci (n = 46), viridans group streptococci (n = 100), Streptococcus milleri (n = 18) and enterococci (n = 161) by an agar dilution technique. In addition, time-kill studies were performed to estimate the bactericidal activity of trovafloxacin against S. milleri and viridans group streptococci. Trovafloxacin was the most active agent tested against staphylococci. It also showed good activity, at least four-fold and usually eight- to 16-fold that of ciprofloxacin, against all the streptococci. Trovafloxacin showed good activity against vancomycin-sensitive Enterococcus faecalis and Enterococcus faecium, but was less active against the 11 isolates of vancomycin-resistant enterococci. Trovafloxacin showed comparable or superior bactericidal activity to amoxycillin against the S. milleri and viridans group streptococci tested.

UR - http://www.scopus.com/inward/record.url?scp=0030756870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030756870&partnerID=8YFLogxK

U2 - 10.1093/jac/39.suppl_2.57

DO - 10.1093/jac/39.suppl_2.57

M3 - Article

VL - 39

SP - 57

EP - 62

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - SUPPL. B

ER -